Hairy cell leukemia (HCL) is a B-cell chronic lymphoproliferative disorder that was initially described as leukemic reticuloendotheliosis. The disease is characterized by monocytopenia, organomegaly, constitutional symptoms, and bone marrow fbrosis. Signifcant advances have improved the diagnosis and management of HCL over the last 55 years. Although HCL has an indolent course, most patients will require treatment of the disease. Indications to initiate therapy include disease-related symptoms, signs of bone marrow failure, or frequent infections. Asymptomatic patients without cytopenias can be observed without the need for therapeutic interventions. Therapeutic options usually consist of chemotherapy, immunotherapy, biological agents, and surgery.
H airy cell leukemia (HCL) was initially described in 1958 as leukemic reticuloendotheliosis. 1 Te disorder is rare and accounts for 2% of all adult leukemia cases in the United States. 2 Te incidence rate is 0.3 cases per 100,000 population per year, with about 600 individuals diagnosed annually. 2, 3 Men are afected 4 times more frequently than are women. Te incidence is higher in whites than in blacks. [3] [4] [5] Te average age of diagnosis is 52 years. 6 Te exact etiology remains unknown. 5 
Diagnosis of HCL

Clinical presentation
About 25% of individuals with HCL have no signs or symptoms at the initial presentation. Most patients experience fatigue and generalized weakness. Tey may also complain of unexplained weight loss, pain in the left upper quadrant, recurrent infections, and bruising. Physical examination may reveal hepatosplenomegaly and lymphadenopathy. Dermatologic manifestations are common and include ecchymosis, purpura, zoster rash, cellulitis, abscess, pyoderma, and dermatophytosis. 
Laboratory fndings
Anemia, leukopenia, monocytopenia, and neutropenia are the most frequent hematologic abnormalities seen in patients with HCL. 1 Other laboratory fndings may include thrombocytopenia and hypocholesterolemia. Autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenia purpura (ITP) can also be observed. 3 Te peripheral blood smear demonstrates atypical lymphocytes with hairlike projections ( Figure) . An attempted bone marrow aspiration that is unsuccessful -as is often the case in HCL -is called a "dry tap." 7 Flow cytometry of the peripheral blood or the bone marrow may reveal cells that are positive for certain clusters of diferentiation (specifcally, CD11c, CD19, CD20, CD22, CD25, CD103, and CD123) as well as surface-membrane immunoglobulin free light chains (κ or λ) but are negative for CD5, CD21, and CD23. 7 Additional markers -such as cyclin D1, annexin A1, tartrate-resistant acid phosphotase (TRAP), the monoclonal antibody DBA.44, and the BRAF V600E mutation -are usually expressed by the malignant cell population. [7] [8] [9] Te bone marrow biopsy is also remarkable for varying degrees of reticulin and collagen fbrosis. 
Diferential diagnosis
Te diferential diagnosis of HCL should include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), splenic marginal zone lymphoma (SMZL), HCL-variant, myelodysplastic syndrome (MDS), and primary myelofbrosis (PMF).
Treatment in HCL
Asymptomatic patients are usually observed because there is no proven clinical beneft in early treatment. [19] [20] [21] Reasons to begin therapy would include the presence of severe fatigue and weakness that interfere with the patient's quality of life; symptomatic splenomegaly or lymphadenopathy; signs of bone marrow failure (ie, a hemoglobin level < 10 g/dL, a platelet count < 100,000/μL and an absolute neutrophil count < 1,000/μL and the occurrence of frequent infections. 20 Pharmacologic therapy consists of purine analogs, interferon, and monoclonal antibodies. [6] [7] [19] [20] Other treatment options may include splenectomy and splenic irradiation.
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Splenectomy Historically, splenectomy was the only available treatment option for patients with HCL and symptomatic splenomegaly; it relieved symptoms related to an enlarged spleen and temporarily improved cytopenias. 21 However, splenectomy is associated with a risk of hemorrhage, which is the second most common cause of death in patients with HCL, thus making it challenging to perform, especially in older patients. 22 Currently, splenectomy is reserved for patients with primary splenic HCL who are refractory to medical therapy, for patients with splenic rupture, or for diagnostic purposes.
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Interferon
Te frst reports of signifcant clinical activity in HCL via interferon-alpha (IFN-α) were made in 1984; these investigators reported on 7 patients who had a 43% complete remission (CR) and a partial remission (PR) of 57%. 23 In a small, randomized, 1992 study comparing IFN-α vs splenectomy, patients who received IFN-α showed higher responses and had longer median times both to response and to treatment failure. 24 IFN-α became the frst medical therapy that demonstrated clinical beneft over splenectomy, producing mostly partial responses. Tis study showed that medical therapy could be successfully given to patients with HCL-related cytopenias.
In 1995, researchers reported the long-term follow-up of 55 previously untreated HCL patients after 1 year of treatment with IFN-α. 25 Te overall response rate (ORR) was 73%, with a CR of 49% and a PR of 24%; in all, 83% (46 patients) remained alive at 6 years. Currently, IFN-α is used for HCL patients with relapsed and/or refractory disease after purine analogs. 6, [20] [21] 26 Purine analogs Clinical trials evaluating purine analogs in HCL, including pentostatin and cladribine, have demonstrated improved tolerability and ORR; reduction in size of spleen and lymph nodes; and longer time to progression.
Te frst report of treating HCL with pentostatin was published in 1984, when 2 patients with advanced HCL both achieved a CR with the drug. 27 In 1995, a large intergroup trial compared pentostatin vs IFN-α; patients who received pentostatin showed a signifcantly higher ORR (79% vs 38%) and CR (76% vs 11%). 28 Relapse-free survival (RFS) was also higher for those in the pentostatin group, but overall survival (OS) was not signifcantly diferent between the 2 therapies. 28, 29 Currently, cladribine is considered to be the treatment of choice because of its short duration of therapy, favorable adverse-efect profle, durable response rates, and improvement in disease-free survival. 30 In 1990, a single-institution trial of 12 patients who were treated with 1 cycle of cladribine showed an ORR of 100% and a CR of 92%. 31 In addition, other reports of treatment-naive patients with HCL have shown ORRs ranging between 98% and 100%, with CRs ranging between 76% and 95% (Table) . [32] [33] [34] [35] [36] [37] [38] [39] Relapsed disease after the initial therapy can be either retreated with another course of cladribine or switched to pentostatin. 6, 19, 20 Monoclonal antibodies Monoclonal antibodies have been evaluated in the treatment of HCL in a number of small clinical trials.
Rituximab is a chimeric, murine monoclonal antibody against CD20 and an active agent in treating B-cell lymphoid disorders. Te frst report of successful therapy with rituximab in a patient with HCL that was refractory to cladribine was published in 1999. 40 A year later, a case study reported a CR with rituximab therapy in an HCL patient. 41 In 2001, a report of 11 patients who were treated with rituximab as a single agent noted that 6 of them achieved a CR and 1 achieved a PR, with an ORR of 64%. 42 A single-institution trial of 15 Review patients who were treated with weekly rituximab therapy showed an ORR of 80% and a CR of 53%. 43 A phase 2 trial of rituximab in patients who previously failed cladribine therapy showed an ORR of 24% and a CR of 12%. 44 Monotherapy with rituximab demonstrated good tolerability, with ORRs ranging between 24% and 80%, and CRs between 12% and 53%. [42] [43] [44] [45] Rituximab also has been evaluated in combination with purine analogs in the relapsed/refractory setting, and was shown to be efective in eradicating minimally residual disease that can be detected by immunophenotyping by fow cytometry, immunohistochemistry, and polymerase chain reaction. 46, 47 Te lack of data from large, prospective, randomized trials precludes the routine use of this agent in the upfront setting.
Alemtuzumab is a monoclonal antibody that is approved by the US Food and Drug Administration for the treatment of CLL. It is a humanized, anti-CD52 antibody that could be used in the relapsed setting. 48, 49 However, additional trials are needed to formally establish it as a therapeutic option in HCL.
Te role of monoclonal antibodies in the treatment of HCL remains largely undefned because there have been no large prospective studies to support their use; for patients in the relapsed/refractory setting, enrolment in clinical trials that are evaluating these biologics is most appropriate.
Radiation therapy
Radiation therapy has been used largely for the treatment of skeleton-related complications associated with HCL, such as lytic lesions. 21 Splenic irradiation is rarely used as a treatment modality, mostly because of the availability of other efective treatment options, as previously mentioned in this review. Currently, radiation is reserved for patients who have symptomatic splenomegaly and are not good candidates for other therapeutic options.
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Novel therapies
Tere are several novel therapies in the early phases of development. Tey include anti-CD22 (BL-22) and anti-CD25 (LMB-2) monoclonal antibodies. 51, 52 In 2000, a report of 4 patients who were treated with LMB-2 (a recombinant immunotoxin against CD25) noted that 3 of them achieved a PR and 1 achieved a CR. 51 In 2005, a phase I study of 31 patients who were treated with BL-22 (an anti-CD 22 recombinant immunotoxin) resulted in an ORR of 80%, with a CR of 61% and a PR of 19%. 52 In 2011, the BRAF V600E mutation was found in all 47 HCL patients. 8 Vemurafenib (a BRAF inhibitor that has shown clinical beneft in patients with advanced forms of melanoma) has also recently been shown to have activity as a single agent in the treatment of refractory HCL. [53] [54] [55] Complications in HCL Patients with HCL are susceptible to infectious complications. Tey can develop anemia, thrombocytopenia, neutropenia, monocytopenia, or platelet dysfunction at any time during their disease course. 3 Other complications include lytic bone lesions, infammatory arthritis, vasculitis, and Tcell dysfunction. Splenic rupture has also been reported. 3, 22 Although infections are the most common cause of death in these patients, there are no established recommendations for routine antimicrobial, antiviral, or antifungal prophylaxis. 20 Individuals with HCL also appear to be at a higher risk for the development of secondary malignancies.
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Conclusion HCL is a rare, B-cell chronic lymphoproliferative disorder. Te disease is indolent, so patients should be observed until they develop signs or symptoms of disease progression. Tose who require therapy are initially treated with purine analogs. Other therapeutic options include monoclonal antibodies, IFN-α, and splenectomy when clinically warranted. Monoclonal antibodies can be used alone or in combination with purine analogs, and are currently being evaluated in clinical trials. Future directions include the development of novel targeted therapies; further evaluation of monoclonal antibodies as single agents and in combination in the upfront setting; and subsequent lines of therapy in well-designed clinical trials.
FIGURE 1
An atypical lymphocyte with hairlike projections can be seen on a peripheral blood smear (Wright's stain, 1,000x magnifcation).
